168 related articles for article (PubMed ID: 30201983)
1. NT5C2 germline variants alter thiopurine metabolism and are associated with acquired NT5C2 relapse mutations in childhood acute lymphoblastic leukaemia.
Tulstrup M; Grosjean M; Nielsen SN; Grell K; Wolthers BO; Wegener PS; Jonsson OG; Lund B; Harila-Saari A; Abrahamsson J; Vaitkeviciene G; Pruunsild K; Toft N; Holm M; Hulegårdh E; Liestøl S; Griskevicius L; Punab M; Wang J; Carroll WL; Zhang Z; Dalgaard MD; Gupta R; Nersting J; Schmiegelow K
Leukemia; 2018 Dec; 32(12):2527-2535. PubMed ID: 30201983
[TBL] [Abstract][Full Text] [Related]
2. Effects of NT5C2 Germline Variants on 6-Mecaptopurine Metabolism in Children With Acute Lymphoblastic Leukemia.
Jiang C; Yang W; Moriyama T; Liu C; Smith C; Yang W; Qian M; Li Z; Tulstrup M; Schmiegelow K; Crews KR; Zhang H; Pui CH; Evans W; Relling M; Bhatia S; Yang JJ
Clin Pharmacol Ther; 2021 Jun; 109(6):1538-1545. PubMed ID: 33124053
[TBL] [Abstract][Full Text] [Related]
3. NUDT15 polymorphism and NT5C2 and PRPS1 mutations influence thiopurine sensitivity in acute lymphoblastic leukaemia cells.
Somazu S; Tanaka Y; Tamai M; Watanabe A; Kagami K; Abe M; Harama D; Shinohara T; Akahane K; Goi K; Sugita K; Moriyama T; Yang J; Goto H; Minegishi M; Iwamoto S; Takita J; Inukai T
J Cell Mol Med; 2021 Nov; 25(22):10521-10533. PubMed ID: 34636169
[TBL] [Abstract][Full Text] [Related]
4. DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trial.
Nielsen SN; Grell K; Nersting J; Abrahamsson J; Lund B; Kanerva J; Jónsson ÓG; Vaitkeviciene G; Pruunsild K; Hjalgrim LL; Schmiegelow K
Lancet Oncol; 2017 Apr; 18(4):515-524. PubMed ID: 28258828
[TBL] [Abstract][Full Text] [Related]
5. Role of TPMT and ITPA variants in mercaptopurine disposition.
Gerbek T; Ebbesen M; Nersting J; Frandsen TL; Appell ML; Schmiegelow K
Cancer Chemother Pharmacol; 2018 Mar; 81(3):579-586. PubMed ID: 29387964
[TBL] [Abstract][Full Text] [Related]
6. No association between relapse hazard and thiopurine methyltransferase geno- or phenotypes in non-high risk acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study.
Nielsen SN; Toksvang LN; Grell K; Nersting J; Abrahamsson J; Lund B; Kanerva J; Jónsson ÓG; Vaitkeviciene G; Pruunsild K; Appell ML; Hjalgrim LL; Schmiegelow K
Cancer Chemother Pharmacol; 2021 Aug; 88(2):271-279. PubMed ID: 33928426
[TBL] [Abstract][Full Text] [Related]
7. Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL.
Tzoneva G; Perez-Garcia A; Carpenter Z; Khiabanian H; Tosello V; Allegretta M; Paietta E; Racevskis J; Rowe JM; Tallman MS; Paganin M; Basso G; Hof J; Kirschner-Schwabe R; Palomero T; Rabadan R; Ferrando A
Nat Med; 2013 Mar; 19(3):368-71. PubMed ID: 23377281
[TBL] [Abstract][Full Text] [Related]
8. Thioguanine versus mercaptopurine for therapy of childhood lymphoblastic leukaemia: a comparison of haematological toxicity and drug metabolite concentrations.
Lancaster DL; Lennard L; Rowland K; Vora AJ; Lilleyman JS
Br J Haematol; 1998 Jul; 102(2):439-43. PubMed ID: 9695957
[TBL] [Abstract][Full Text] [Related]
9. Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia.
Tzoneva G; Dieck CL; Oshima K; Ambesi-Impiombato A; Sánchez-Martín M; Madubata CJ; Khiabanian H; Yu J; Waanders E; Iacobucci I; Sulis ML; Kato M; Koh K; Paganin M; Basso G; Gastier-Foster JM; Loh ML; Kirschner-Schwabe R; Mullighan CG; Rabadan R; Ferrando AA
Nature; 2018 Jan; 553(7689):511-514. PubMed ID: 29342136
[TBL] [Abstract][Full Text] [Related]
10. Structure and Mechanisms of NT5C2 Mutations Driving Thiopurine Resistance in Relapsed Lymphoblastic Leukemia.
Dieck CL; Tzoneva G; Forouhar F; Carpenter Z; Ambesi-Impiombato A; Sánchez-Martín M; Kirschner-Schwabe R; Lew S; Seetharaman J; Tong L; Ferrando AA
Cancer Cell; 2018 Jul; 34(1):136-147.e6. PubMed ID: 29990496
[TBL] [Abstract][Full Text] [Related]
11. Dynamics of leucocyte DNA thioguanine nucleotide levels during maintenance therapy of childhood acute lymphoblastic leukemia.
Larsen RH; Hjalgrim LL; Degn M; Nersting J; Als-Nielsen B; Grell K; Schmiegelow K
Cancer Chemother Pharmacol; 2021 Jul; 88(1):53-60. PubMed ID: 33754188
[TBL] [Abstract][Full Text] [Related]
12. Subclonal NT5C2 mutations are associated with poor outcomes after relapse of pediatric acute lymphoblastic leukemia.
Barz MJ; Hof J; Groeneveld-Krentz S; Loh JW; Szymansky A; Astrahantseff K; von Stackelberg A; Khiabanian H; Ferrando AA; Eckert C; Kirschner-Schwabe R
Blood; 2020 Mar; 135(12):921-933. PubMed ID: 31971569
[TBL] [Abstract][Full Text] [Related]
13. CRISPR/Cas9-Mediated Induction of Relapse-Specific
Nguyen TTT; Tanaka Y; Sanada M; Hosaka M; Tamai M; Kagami K; Komatsu C; Somazu S; Harama D; Kasai S; Watanabe A; Akahane K; Goi K; Inukai T
Mol Pharmacol; 2023 Apr; 103(4):199-210. PubMed ID: 36669880
[TBL] [Abstract][Full Text] [Related]
14. The effects of inherited NUDT15 polymorphisms on thiopurine active metabolites in Japanese children with acute lymphoblastic leukemia.
Moriyama T; Nishii R; Lin TN; Kihira K; Toyoda H; Jacob N; Kato M; Koh K; Inaba H; Manabe A; Schmiegelow K; Yang JJ; Hori H
Pharmacogenet Genomics; 2017 Jun; 27(6):236-239. PubMed ID: 28445187
[TBL] [Abstract][Full Text] [Related]
15. Genetics and mechanisms of NT5C2-driven chemotherapy resistance in relapsed ALL.
Dieck CL; Ferrando A
Blood; 2019 May; 133(21):2263-2268. PubMed ID: 30910786
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic Inhibition of NT5C2 Reverses Genetic and Nongenetic Drivers of 6-MP Resistance in Acute Lymphoblastic Leukemia.
Reglero C; Dieck CL; Zask A; Forouhar F; Laurent AP; Lin WW; Albero R; Miller HI; Ma C; Gastier-Foster JM; Loh ML; Tong L; Stockwell BR; Palomero T; Ferrando AA
Cancer Discov; 2022 Nov; 12(11):2646-2665. PubMed ID: 35984649
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of
Moriyama T; Liu S; Li J; Meyer J; Zhao X; Yang W; Shao Y; Heath R; Hnízda A; Carroll WL; Yang JJ
Mol Cancer Ther; 2019 Oct; 18(10):1887-1895. PubMed ID: 31358663
[TBL] [Abstract][Full Text] [Related]
18. Measures of 6-mercaptopurine and methotrexate maintenance therapy intensity in childhood acute lymphoblastic leukemia.
Nielsen SN; Grell K; Nersting J; Frandsen TL; Hjalgrim LL; Schmiegelow K
Cancer Chemother Pharmacol; 2016 Nov; 78(5):983-994. PubMed ID: 27600880
[TBL] [Abstract][Full Text] [Related]
19. DNA-thioguanine nucleotide as a treatment marker in acute lymphoblastic leukemia patients with NUDT15 variant genotypes.
Ju HY; Lee JW; Cho HW; Hyun JK; Ma Y; Yi ES; Yoo KH; Sung KW; Choi R; Koo HH; Lee SY
PLoS One; 2021; 16(1):e0245667. PubMed ID: 33481917
[TBL] [Abstract][Full Text] [Related]
20. Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia.
Meyer JA; Wang J; Hogan LE; Yang JJ; Dandekar S; Patel JP; Tang Z; Zumbo P; Li S; Zavadil J; Levine RL; Cardozo T; Hunger SP; Raetz EA; Evans WE; Morrison DJ; Mason CE; Carroll WL
Nat Genet; 2013 Mar; 45(3):290-4. PubMed ID: 23377183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]